167 related articles for article (PubMed ID: 20652347)
1. Long-term outcomes of three-dimensional conformal radiation therapy combined with neoadjuvant hormonal therapy in Japanese patients with locally advanced prostate cancer.
Sakamoto M; Mizowaki T; Mitsumori M; Takayama K; Sasai K; Norihisa Y; Kamoto T; Nakamura E; Ogawa O; Hiraoka M
Int J Clin Oncol; 2010 Dec; 15(6):571-7. PubMed ID: 20652347
[TBL] [Abstract][Full Text] [Related]
2. Long-term outcomes of three-dimensional conformal radiation therapy combined with neoadjuvant hormonal therapy for Japanese patients with T1c-T2N0M0 prostate cancer.
Mizowaki T; Takayama K; Norihisa Y; Ogura M; Kamba T; Inoue T; Shimizu Y; Kamoto T; Ogawa O; Hiraoka M
Int J Clin Oncol; 2012 Dec; 17(6):562-8. PubMed ID: 21968911
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcomes of dynamic conformal arc irradiation combined with neoadjuvant hormonal therapy in Japanese patients with T1c-T2N0M0 prostate cancer: case series study.
Ikeda I; Mizowaki T; Norihisa Y; Takayama K; Kamba T; Inoue T; Nakamura E; Kamoto T; Ogawa O; Hiraoka M
Jpn J Clin Oncol; 2014 Feb; 44(2):180-5. PubMed ID: 24379210
[TBL] [Abstract][Full Text] [Related]
4. The external radiotherapy with three-dimensional conformal boost after the neoadjuvant androgen suppression for patients with locally advanced prostatic carcinoma.
Sumi M; Ikeda H; Tokuuye K; Kagami Y; Murayama S; Tobisu K; Kakizoe T
Int J Radiat Oncol Biol Phys; 2000 Sep; 48(2):519-28. PubMed ID: 10974471
[TBL] [Abstract][Full Text] [Related]
5. Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer.
Stock RG; Stone NN
Brachytherapy; 2002; 1(1):2-10. PubMed ID: 15062181
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes of intensity-modulated radiation therapy combined with neoadjuvant androgen deprivation therapy under an early salvage policy for patients with T3-T4N0M0 prostate cancer.
Mizowaki T; Norihisa Y; Takayama K; Ikeda I; Inokuchi H; Nakamura K; Kamba T; Inoue T; Kamoto T; Ogawa O; Hiraoka M
Int J Clin Oncol; 2016 Feb; 21(1):148-55. PubMed ID: 26141133
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant LHRH analog plus estramustine phosphate combined with three-dimensional conformal radiotherapy for intermediate- to high-risk prostate cancer: a randomized study.
Hirano D; Nagane Y; Satoh K; Mochida J; Sugimoto S; Ichinose T; Takahashi S; Maebayashi T; Saitoh T
Int Urol Nephrol; 2010 Mar; 42(1):81-8. PubMed ID: 19449118
[TBL] [Abstract][Full Text] [Related]
8. Ten-year outcomes of intensity-modulated radiation therapy combined with neoadjuvant hormonal therapy for intermediate- and high-risk patients with T1c-T2N0M0 prostate cancer.
Mizowaki T; Norihisa Y; Takayama K; Ikeda I; Inokuchi H; Nakamura K; Kamba T; Inoue T; Kamoto T; Ogawa O; Hiraoka M
Int J Clin Oncol; 2016 Aug; 21(4):783-790. PubMed ID: 26843024
[TBL] [Abstract][Full Text] [Related]
9. Three-dimensional conformal therapy versus standard radiation therapy in localized carcinoma of prostate: an update.
Perez CA; Michalski JM; Mansur D; Lockett MA
Clin Prostate Cancer; 2002 Sep; 1(2):97-104. PubMed ID: 15046700
[TBL] [Abstract][Full Text] [Related]
10. Rotational 3D-conformal radiation therapy (conformation therapy) combined with hormone therapy for the treatment of stage B2/C prostate cancer in Japanese men.
Karasawa K; Kaizu T; Niibe Y; Igaki H; Shinohara M; Tanaka Y; Matsuda T
Int J Radiat Oncol Biol Phys; 2003 May; 56(1):208-12. PubMed ID: 12694840
[TBL] [Abstract][Full Text] [Related]
11. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
12. Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer.
Zelefsky MJ; Kelly WK; Scher HI; Lee H; Smart T; Metz E; Schwartz L; Fuks Z; Leibel SA
J Clin Oncol; 2000 May; 18(9):1936-41. PubMed ID: 10784635
[TBL] [Abstract][Full Text] [Related]
13. Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy.
Zelefsky MJ; Lyass O; Fuks Z; Wolfe T; Burman C; Ling CC; Leibel SA
J Clin Oncol; 1998 Oct; 16(10):3380-5. PubMed ID: 9779716
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant hormone therapy for radical prostate radiotherapy: bicalutamide monotherapy vs. luteinizing hormone-releasing hormone agonist monotherapy: a single-institution matched-pair analysis.
McGivern U; Mitchell DM; McDowell C; O'Hare J; Corey G; O'Sullivan JM
Clin Genitourin Cancer; 2012 Sep; 10(3):190-5. PubMed ID: 22677511
[TBL] [Abstract][Full Text] [Related]
15. [Biochemical control after conformal, 3 dimensional radiotherapy of prostatic carcinoma].
Geinitz H; Zimmermann F; von Wedel E; Thamm R; Busch R; Feldmann HJ; Molls M
Strahlenther Onkol; 2002 Jul; 178(7):369-77. PubMed ID: 12163991
[TBL] [Abstract][Full Text] [Related]
16. Current status and outcomes of patients developing PSA recurrence after prostatectomy who were treated with salvage radiotherapy: a JROSG surveillance study.
Mizowaki T; Aoki M; Nakamura K; Yorozu A; Kokubo M; Karasawa K; Kozuka T; Nakajima N; Sasai K; Akimoto T
J Radiat Res; 2015 Jul; 56(4):750-6. PubMed ID: 25910489
[TBL] [Abstract][Full Text] [Related]
17. Results of radiation therapy combined with neoadjuvant hormonal therapy for stage III prostate cancer: comparison of two different definitions of PSA failure.
Mitsumori M; Sasaki Y; Mizowaki T; Takayama K; Nagata Y; Hiraoka M; Negoro Y; Sasai K; Kinoshita H; Kamoto T; Ogawa O
Int J Clin Oncol; 2006 Oct; 11(5):396-402. PubMed ID: 17058138
[TBL] [Abstract][Full Text] [Related]
18. Three-dimensional conformal therapy or standard irradiation in localized carcinoma of prostate: preliminary results of a nonrandomized comparison.
Perez CA; Michalski JM; Purdy JA; Wasserman TH; Williams K; Lockett MA
Int J Radiat Oncol Biol Phys; 2000 Jun; 47(3):629-37. PubMed ID: 10837945
[TBL] [Abstract][Full Text] [Related]
19. A systematic overview of radiation therapy effects in prostate cancer.
Nilsson S; Norlén BJ; Widmark A
Acta Oncol; 2004; 43(4):316-81. PubMed ID: 15303499
[TBL] [Abstract][Full Text] [Related]
20. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
